Predict your next investment

DNALite Therapeutics company logo
HEALTHCARE | Drug Development
dnalite.com

See what CB Insights has to offer

Founded Year

2016

Stage

Convertible Note - II | Alive

Total Raised

$1.7M

About DNALite Therapeutics

DNALite Therapeutics is making DNA based gene-therapy drugs for the gastrointestinal (GI) tract by leveraging new drug delivery technologies. Its current target is Familial Adenomatous Polyposis (FAP). FAP patients develop colorectal and duodenal cancer at high rates and must undergo surgeries at young ages. The company's drug is aimed to remove these surgeries completely.

DNALite Therapeutics Headquarter Location

455 Mission Bay Boulevard South

San Francisco, California, 94158,

United States

Latest DNALite Therapeutics News

UC Berkeley backs oral gene therapy company targeting the gut in $1.5M seed round

Aug 10, 2018

Aug 10, 2018 10:15am The company's first target is a single-gene inherited disorder that causes hundreds of polyps to form in the colon, by using a nonviral nanoparticle that mimics enteroviruses to bypass mucus barriers. (Pixabay) A UC Berkeley-backed preclinical company, DNAlite Therapeutics, has gathered $1.5 million in seed money to pursue oral gene therapies that can slip through the mucus barrier that typically blocks access to the gastrointestinal tract. Its first target is familial adenomatous polyposis, a rare, inherited disorder that causes hundreds of polyps to form in the walls of the colon, eventually turning malignant unless the large intestine is removed. DNAlite’s nonviral nanoparticle platform mimics certain properties of enteroviruses—a common cause of the stomach flu, as well as polio, meningitis and other diseases—in order to deliver a functional copy of a defective gene to the gastrointestinal epithelium. Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox! “Using a nonviral system allows us to overcome packaging capacity and immune response, which is a common challenge with current viral vectors,” DNAlite’s VP of business development and operations Xixi Zhu told FierceBiotech. The company has “several strategies” to overcome the volatile, acidic environment of the stomach and small intestine, she said. After proving itself against diseases involving a single defective gene, the company plans to move on to more prevalent GI conditions such as inflammatory bowel disease, Zhu said, adding that the delivery platform can be adapted to other insulated tissues, such as the respiratory tract, sinuses, reproductive tract and the eyes. The Berkeley Catalyst Fund led the seed round , with participation from the university, SVE Capital, Blue Bear Ventures, SOSV and the Baldota family. In addition, the San Francisco-based company received an investment from the Chinese pharma company BrightGene Bio-Medical Technology. DNAlite’s immediate plans include refining its delivery system and demonstrating efficacy in an animal model. While attending UC Berkeley, co-founders Mubhij Ahmad and Timothy Day conducted their initial experiments at the university’s core facility, as well as through contract research organizations off-site in their spare time, Zhu said, with DNAlite holding its own patents since its founding in 2016. “That being said, we were lucky to be a part of the UC system as they have enabled us to receive tremendous support and progress quickly with our programs,” she said. Read more on

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DNALite Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DNALite Therapeutics is included in 3 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

DNALite Therapeutics Patents

DNALite Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Applied genetics
  • Biotechnology
  • Gene delivery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/10/2017

Molecular biology, Biotechnology, Gene therapy, Applied genetics, Gene delivery

Application

Application Date

11/10/2017

Grant Date

Title

Related Topics

Molecular biology, Biotechnology, Gene therapy, Applied genetics, Gene delivery

Status

Application

DNALite Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DNALite Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.